Your browser doesn't support javascript.
loading
Picalm reduction exacerbates tau pathology in a murine tauopathy model.
Ando, Kunie; De Decker, Robert; Vergara, Cristina; Yilmaz, Zehra; Mansour, Salwa; Suain, Valérie; Sleegers, Kristel; de Fisenne, Marie-Ange; Houben, Sarah; Potier, Marie-Claude; Duyckaerts, Charles; Watanabe, Toshio; Buée, Luc; Leroy, Karelle; Brion, Jean-Pierre.
Afiliação
  • Ando K; Laboratory of Histology, Neuroanatomy and Neuropathology, UNI (ULB Neuroscience Institute), Faculty of Medicine, Université Libre de Bruxelles, 808 route de Lennik, Bldg GE, 1070, Brussels, Belgium. Kunie.Ando@ulb.ac.be.
  • De Decker R; Laboratory of Histology, Neuroanatomy and Neuropathology, UNI (ULB Neuroscience Institute), Faculty of Medicine, Université Libre de Bruxelles, 808 route de Lennik, Bldg GE, 1070, Brussels, Belgium.
  • Vergara C; Laboratory of Histology, Neuroanatomy and Neuropathology, UNI (ULB Neuroscience Institute), Faculty of Medicine, Université Libre de Bruxelles, 808 route de Lennik, Bldg GE, 1070, Brussels, Belgium.
  • Yilmaz Z; Laboratory of Histology, Neuroanatomy and Neuropathology, UNI (ULB Neuroscience Institute), Faculty of Medicine, Université Libre de Bruxelles, 808 route de Lennik, Bldg GE, 1070, Brussels, Belgium.
  • Mansour S; Laboratory of Histology, Neuroanatomy and Neuropathology, UNI (ULB Neuroscience Institute), Faculty of Medicine, Université Libre de Bruxelles, 808 route de Lennik, Bldg GE, 1070, Brussels, Belgium.
  • Suain V; Laboratory of Histology, Neuroanatomy and Neuropathology, UNI (ULB Neuroscience Institute), Faculty of Medicine, Université Libre de Bruxelles, 808 route de Lennik, Bldg GE, 1070, Brussels, Belgium.
  • Sleegers K; Neurodegenerative Brain Diseases Group, VIB Center for Molecular Neurology, University of Antwerp, Universiteitsplein 1, 2610, Antwerp, Belgium.
  • de Fisenne MA; Laboratory of Histology, Neuroanatomy and Neuropathology, UNI (ULB Neuroscience Institute), Faculty of Medicine, Université Libre de Bruxelles, 808 route de Lennik, Bldg GE, 1070, Brussels, Belgium.
  • Houben S; Laboratory of Histology, Neuroanatomy and Neuropathology, UNI (ULB Neuroscience Institute), Faculty of Medicine, Université Libre de Bruxelles, 808 route de Lennik, Bldg GE, 1070, Brussels, Belgium.
  • Potier MC; Sorbonne Universités, UPMC Univ Paris 06 UMR S 1127, and Inserm, U 1127, and CNRS UMR 7225, and ICM, 75013, Paris, France.
  • Duyckaerts C; Sorbonne Universités, UPMC Univ Paris 06 UMR S 1127, and Inserm, U 1127, and CNRS UMR 7225, and ICM, 75013, Paris, France.
  • Watanabe T; Laboratoire de Neuropathologie Escourolle, Hôpital de La Pitié-Salpêtrière, AP-HP, Paris, France.
  • Buée L; Department of Biological Science, Graduate School of Humanities and Sciences, Nara Women's University, Nara, Japan.
  • Leroy K; University of Lille, Inserm, CHU-Lille, Alzheimer and Tauopathies, LabEx DISTALZ, 59000, Lille, France.
  • Brion JP; Laboratory of Histology, Neuroanatomy and Neuropathology, UNI (ULB Neuroscience Institute), Faculty of Medicine, Université Libre de Bruxelles, 808 route de Lennik, Bldg GE, 1070, Brussels, Belgium.
Acta Neuropathol ; 139(4): 773-789, 2020 04.
Article em En | MEDLINE | ID: mdl-31925534
Genome-wide association studies (GWAS) have identified PICALM as one of the most significant susceptibility loci for late-onset Alzheimer's disease (AD) after APOE and BIN1. PICALM is a clathrin-adaptor protein and plays critical roles in clathrin-mediated endocytosis and in autophagy. PICALM modulates brain amyloid ß (Aß) pathology and tau accumulation. We have previously reported that soluble PICALM protein level is reduced in correlation with abnormalities of autophagy markers in the affected brain areas of neurodegenerative diseases including AD, sporadic tauopathies and familial cases of frontotemporal lobar degeneration with tau-immunoreactive inclusions (FTLD-tau) with mutations in the microtubule-associated protein tau (MAPT) gene. It remains unclarified whether in vivo PICALM reduction could either trigger or influence tau pathology progression in the brain. In this study, we confirmed a significant reduction of soluble PICALM protein and autophagy deficits in the post-mortem human brains of FTLD-tau-MAPT (P301L, S364S and L266V). We generated a novel transgenic mouse line named Tg30xPicalm+/- by crossing Tg30 tau transgenic mice with Picalm-haploinsufficient mice to test whether Picalm reduction may modulate tau pathology. While Picalm haploinsufficiency did not lead to any motor phenotype or detectable tau pathology in mouse brains, Tg30xPicalm+/- mice developed markedly more severe motor deficits than Tg30 by the age of 9 months. Tg30xPicalm+/- had significantly higher pathological tau levels in the brain, an increased density of neurofibrillary tangles compared to Tg30 mice and increased abnormalities of autophagy markers. Our results demonstrate that Picalm haploinsufficiency in transgenic Tg30 mice significantly aggravated tau pathologies and tau-mediated neurodegeneration, supporting a role for changes in Picalm expression as a risk/sensitizing factor for development of tau pathology and as a mechanism underlying the AD risk associated to PICALM.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Tauopatias / Proteínas Monoméricas de Montagem de Clatrina Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Tauopatias / Proteínas Monoméricas de Montagem de Clatrina Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article